Pharmaceutical companies have aspired to make medication adherence programs more effective for years. A report from Credit Suisse shows that increased adherence could substantially increase revenue from 2020–2026 for leading pharma companies such as Merck, Pfizer, Bristol Myers Squibb, Johnson…
Are you measuring what matters most for your brand? Many key performance indicators (KPIs) are used to measure the success of adherence programs, and they can vary across different pharmaceutical companies. According to Andrea Kasprzyk, Director of Sales at AllazoHealth,…
We live in exciting times for adherence, and the pharma industry is playing a critical role, according to Mark Degatano, a pharmaceutical industry analytics expert who is on the advisory board of AllazoHealth. Degatano’s expertise comes from 24 years with…
Eli Lilly and Co. and Abbott have made headlines recently for using real-world evidence to prove better adherence and outcomes for its diabetes products. More pharma companies are likely to utilize real world data to support brands as access improves.…
With medication non-adherence costing the industry more than $600 billion a year, many pharmaceutical companies are creating medication adherence programs, often in conjunction with pharmacists and payers. According to Andrea Kasprzyk, Director of Sales at AllazoHealth, "The objective of an…
Besides being a financial issue for pharmaceutical companies, unfilled prescriptions can lead to poorer health outcomes, drive up overall cost of care, and can have an impact on provider performance under value-based payment models. Pharmaceutical companies often use copay assistance…
A leading pharmaceutical company engaged AllazoHealth on a multi-year project using artificial intelligence to optimize a patient support program for a major product. Overcoming an adherence challenge The pharmaceutical company faced a challenge: An estimated 50% of patents stopped taking…